LMLN and leishmaniasis: Another study performed by Chowdhury et al. (2019), designed two siRNAs and three miRNAs that had L. donovani GP63 as their exclusive target, demonstrating that these molecules can be used to inhibit the expression of GP63 and act as one more therapeutic tool for tackling leishmaniasis [103].